Akebia Therapeutics, Inc.’s AKBA share price has surged by 11.37%, which has investors questioning if this is right time to ...

1Molecular and Cell Biology Laboratory, Salk Institute for Biological Studies, La Jolla, California.

This summary highlights only some of the key features and terms of the actual license. It is not a license and has no legal value. Carefully review the actual license before using these materials.

Anemia is a common condition in premature infants, particularly those at risk for retinopathy of prematurity (ROP). While the ...

Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in ...

We are pleased to announce our latest publication on Desidustat titled “Prolyl hydroxylase inhibitor desidustat improves stroke outcomes via enhancing efferocytosis in mice with chronic kidney ...

Despite finally winning a hard-fought FDA approval for its chronic kidney disease (CKD) anemia drug Vafseo last year, Akebia ...

like post-translational modifications such as prolyl hydroxylation and phosphorylation, it has different roles in different contexts. The formation of 5-methylcytosine from cytosine is a well ...

Protein disulfide isomerase plays an essential role in osteoblast differentiation and bone formation through the regulation of collagen prolyl 4-hydroxylase expression, and PDI deficiency in mice ...

Strong results to date of Vafseo U.S. launch; expect Vafseo Q1 2025 net product revenues of approximately $10-$11 millionCash resources and cash ...

Akebia Therapeutics, Inc. (NASDAQ:AKBA – Get Free Report) was the recipient of unusually large options trading activity on Friday. Stock traders bought 3,386 call options on the company. This is an ...